Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Neuroblastoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Head and Neck Neoplasms 4Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Lymphoma 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Neoplasms 2Mouth Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Hodgkin Disease 2Burkitt Lymphoma 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1

Interventions

Cyclophosphamide 45Prednisone 31N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 29Vincristine 28Doxorubicin 27Etoposide 22romidepsin 20Gemcitabine 18Lenalidomide 1610-propargyl-10-deazaaminopterin 16fludarabine phosphate 15Whole-Body Irradiation 15Peripheral Blood Stem Cell Transplantation 14Brentuximab Vedotin 13Azacitidine 13Mycophenolic Acid 12Dexamethasone 10Cyclosporine 10Bortezomib 10Alemtuzumab 10Rituximab 8fludarabine 7belinostat 7Methotrexate 6Cytarabine 6Busulfan 6Bendamustine Hydrochloride 6pembrolizumab 5denileukin diftitox 5Nivolumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × Fenretinide × Clear all
NCT04234048 2025-09-22

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

SciTech Development, Inc.

Phase 1 Recruiting
46 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02495415 2019-07-23

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

CerRx, Inc.

Phase 2 Unknown
140 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡